On Monday, MannKind Corporation (NASDAQ:MNKD)’s shares declined -2.74% to $3.19.
MannKind Corporation (MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, declared that it will present at the Aegis Capital Corp. 2015 Growth Conference on Thursday, October 8, 2015 at 9:30 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s shares gained 8.59% to $2.15.
Arena Pharmaceuticals, Inc. (ARNA) declared that, at the request of the Board of Directors, Jack Lief, Arena’s President and Chief Executive Officer, has stepped down from the company, counting its Board of Directors. Dr. Harry F. Hixson, a director of Arena since 2004, has been designated to serve as interim Chief Executive Officer and interim principal financial officer. Arena will right away initiate a search for a new chief executive officer.
Dr. Hixson served as the Chairman of the board of directors of Sequenom, Inc., a genomics company, from January 2003 to March 2015, and as its Chief Executive Officer from September 2009 to June 2014. He formerly served as Chief Executive Officer of BrainCells Inc., a drug discovery and development company, from 2004 to 2005, as Chief Executive Officer of Elitra Pharmaceuticals Inc., a biopharmaceutical company, from 1998 to 2003, and in various administration positions with Amgen Inc., a biopharmaceutical company, from 1985 to 1991, most recently as President and Chief Operating Officer. Dr. Hixson holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from the University of Chicago and a Ph.D. in Physical Biochemistry from Purdue University.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.
At the end of Monday’s trade, Invesco Ltd. (NYSE:IVZ)‘s shares surged 3.01% to $32.50.
The Board of Trustees of each of the Invesco closed-end funds listed below recently declared the following dividends.
A portion of this distribution is estimated to be from a return of principal rather than net income. The Section 19 notice referenced below provides more information and can be found on the Invesco website at www.invesco.com.
Form 1099-DIV for the calendar year will report distributions for federal income tax purposes. The Fund’s annual report to shareholders will comprise information regarding the tax character of Fund distributions for the fiscal year.
The final determination of the source and tax characteristics of all distributions in 2015 will be made after the end of the year.
In order to comply with the requirements of Section 19 of the Investment Company Act of 1940, each Fund will provide its shareholders of record on the record date with a Section 19 Notice disclosing the sources of its dividend payment when a distribution comprises anything other than net investment income. The Section 19 Notice is not offered for tax reporting purposes but for informational purposes only.
Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds.
3M Co (NYSE:MMM), ended its Monday’s trading session with 2.17% gain, and closed at $146.31.
3M Drug Delivery Systems (3M) and Impel NeuroPharma Inc (Impel) declared a planned alliance aimed at advancing Impel’s revolutionary Precision Olfactory Delivery (POD) technology for the improved Central Nervous System (CNS) delivery of drug products. The alliance further solidifies 3M’s presence as a clear leader in the drug delivery sector and shows its continued commitment to cutting-edge technology.
The alliance with 3M will enable Impel to expedite the development and commercialization of the POD technology and accelerate Impel’s internal pipeline into late-stage clinical trials and subsequent global regulatory submissions. As part of the deal, 3M and Impel will collaborate on programs directed to the continued development and commercialization of POD technology. The alliance will leverage 3M’s experience with inhaled and nasal drug delivery devices. Other details of the transaction were not revealed.
Impel’s POD technology deposits drugs deep into the upper nasal cavity where it can achieve delivery into the brain and central nervous system. POD is a handheld, cost-effective, non-invasive means for delivering CNS therapeutics that can be self-administered by a patient, caregiver, physician, or even family member.
3M Company operates as a diversified technology company worldwide. Its Industrial segment offers tapes; coated, non-woven, and bonded abrasives; adhesives; ceramics; sealants; specialty materials; filtration products; closure systems for personal hygiene products; acoustic systems products; automotive components; abrasion-resistant films; structural adhesives; and paint finishing and detailing products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
